Keith Regnante

City Therapeutics, Inc. (City), a clinical-stage biotechnology company developing next-generation RNA interference (RNAi) therapeutics, has appointed Keith Regnante, MBA, as Chief Financial Officer and Mary Beth DeLena, J.D., as Chief Legal Officer.

Regnante will lead City’s finance organization and capital strategy, while DeLena will oversee legal affairs and corporate governance as the company continues to expand its RNAi platform and therapeutic pipeline.

Regnante brings more than 25 years of public biopharmaceutical finance experience, including serving as CFO at two public companies. He joins City from Keros Therapeutics, where he led the finance organization through a period of significant growth and capital raising.

At Keros, Regnante played a key role in the company’s IPO, two follow-on offerings and the establishment of multiple at-the-market financing facilities. He also contributed to a licensing agreement with Takeda Pharmaceuticals that included a $200 million upfront payment and potential milestone payments of up to $1.1 billion.

Previously, Regnante served as CFO of Wave Life Sciences. Earlier in his career, he held increasingly senior finance positions at Shire Pharmaceuticals and Biogen, covering corporate finance, global R&D finance, investor relations and business development finance.

At Biogen, he contributed to major transactions including the acquisition of Elan Pharmaceuticals’ rights to Tysabri and the company’s merger with IDEC Pharmaceuticals. He began his career as a consultant at Boston Consulting Group and KPMG.

Regnante holds an MBA from the MIT Sloan School of Management and a bachelor’s degree in economics from Tufts University.

The appointments strengthen City Therapeutics’ financial and legal leadership as the company advances its next-generation RNAi platform and expands its clinical-stage pipeline.